Tools4Patient has presented data at the MDS Congress 2021 that predicted the placebo response in Parkinson's disease (PD) in a multi-center, multi-national clinical study.
FREMONT, CA: Tools4Patient, a pioneer in the healthcare industry, aims to accelerate patients' lives by developing and commercializing methods and dada analysis solutions focused on the unique patient behaviors that influence their response to treatment.
Tools4Patient has presented data at the MDS Congress 2021 that predicted the placebo response in Parkinson's disease (PD) in a multi-center, multi-national clinical study. This method of mitigating the negative impact of the placebo response, known as PlacebellTM, is an effective tool for increasing study power in randomized clinical trials (RCTs), resulting in higher success rates and shorter clinical trial timelines and costs.
"Modeling the Placebo Response in Parkinson's Disease" has been presented at the International Parkinson and Movement Disorders Society's MDS Congress 2021. Co-authors of this study include Samuel Branders, Celine Billocq and Alvaro Pereira (Tools4Patient); Gaetan Garraux (University of Liege); Brian Berman (Department of Neurology; VCU School of Medicine); Olivier Rascol (Centre d'Investigation Clinique, INSERM); Glenn Stebbins and Christopher Goetz (Department of Neurological Sciences; Rush University Medical Center).
Tools4Patient's Parkinson's disease study takes Placebell's success as a platform solution for multiple indications to the next level.
